Pat

J-GLOBAL ID：201103064938851583

腎臓癌治療薬

Inventor： 矢野 友啓
Applicant, Patent owner： 財団法人ヒューマンサイエンス振興財団
Agent (1)： 特許業務法人特許事務所サイクス
Gazette classification：特許公報
Application number (International application number)：2004096207
Publication number (International publication number)：2005281176
Patent number：4669959
Application date： Mar. 29, 2004
Publication date： Oct. 13, 2005
Claim (excerpt)：

【請求項1】コネキシン32遺伝子及び非受容体型チロシンキナーゼ阻害剤を含む転移性腎臓癌治療薬であって、前記非受容体型チロシンキナーゼ阻害剤がPP1である、転移性腎臓癌治療薬。

IPC (5)：

A61K 31/519 ( 200 6.01) ,  A61K 35/76 ( 200 6.01) ,  A61K 48/00 ( 200 6.01) ,  A61P 35/00 ( 200 6.01) ,  A61K 31/711 ( 200 6.01)

FI (5)：

A61K 31/519 ,  A61K 35/76 ,  A61K 48/00 ,  A61P 35/00 ,  A61K 31/711

Article cited by the Patent：

Cited by applicant (5)

• Negative growth control of HeLa cells by connexin genes: connexin species specificity.
• Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues.
• Role of Src expression and activation in human cancer.
• The specificities of protein kinase inhibitors: an update.
• Gap junction intercellular communication propagates cell death in cancerous cells

Cited by examiner (5)

• Negative growth control of HeLa cells by connexin genes: connexin species specificity.
• Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues.
• Role of Src expression and activation in human cancer.
• The specificities of protein kinase inhibitors: an update.
• Gap junction intercellular communication propagates cell death in cancerous cells